UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

British journal of cancer, 2007-06, Vol.96 (11), p.1656-1658

2007

Volltextzugriff (PDF)

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

Nature communications, 2018-05, Vol.9 (1), p.1777-14, Article 1777

2018

Volltextzugriff (PDF)

Gastrointestinal Stromal Tumors

Journal of clinical oncology, 2018-01, Vol.36 (2), p.136-143

2018

Volltextzugriff (PDF)

The management of metastatic GIST: current standard and investigational therapeutics

Journal of hematology and oncology, 2021-01, Vol.14 (1), p.2-2, Article 2

2021

Volltextzugriff (PDF)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

British journal of cancer, 2019-03, Vol.120 (6), p.612-620

2019

Volltextzugriff (PDF)

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3128-3139

2021

Volltextzugriff (PDF)

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial

JAMA : the journal of the American Medical Association, 2012-03, Vol.307 (12), p.1265

2012

Volltextzugriff (PDF)

Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras

Annals of surgery, 2021-01, Vol.273 (1), p.128-138

2021

Volltextzugriff (PDF)

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis

Annals of surgery, 2018-08, Vol.268 (2), p.296-302

2018

Volltextzugriff (PDF)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Journal of clinical oncology, 2022-12, Vol.40 (34), p.3918-3928

2022

Volltextzugriff (PDF)

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Journal of clinical oncology, 2020-10, Vol.38 (28), p.3294-3303

2020

Volltextzugriff (PDF)

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

Journal of clinical oncology, 2016-01, Vol.34 (3), p.244-250

2016

Volltextzugriff (PDF)

Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor

Molecular cancer therapeutics, 2018-11, Vol.17 (11), p.2473-2480

2018

Volltextzugriff (PDF)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

British journal of cancer, 2020-03, Vol.122 (5), p.658-667

2020

Volltextzugriff (PDF)

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Annals of surgery, 2013-09, Vol.258 (3), p.422-429

2013

Volltextzugriff (PDF)

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1247-1253

Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)

2010

Volltextzugriff (PDF)

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

Clinical cancer research, 2019-01, Vol.25 (2), p.609-618

2019

Volltextzugriff (PDF)

Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study

Acta oncologica, 2024-05, Vol.63 (1), p.288-293

2024

Volltextzugriff (PDF)

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Journal of clinical oncology, 2008-02, Vol.26 (4), p.626-632

2008

Volltextzugriff (PDF)

MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib

Cell death & disease, 2020-03, Vol.11 (3), p.198-198, Article 198

2020

Volltextzugriff (PDF)

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Clinical cancer research, 2020-04, Vol.26 (8), p.1837-1845

2020

Volltextzugriff (PDF)

Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

Clinical cancer research, 2022-01, Vol.28 (1), p.187-200

2022

Volltextzugriff (PDF)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Clinical cancer research, 2021-12, Vol.27 (23), p.6333-6342

2021

Volltextzugriff (PDF)

1 – 25 von 1.095

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(962)
Mit Volltextzugriff
(1.037)

Publikationsform

Artikel
(1.093)
magazinearticle
(2)

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.015)
Science & Technology
(935)
Life Sciences & Biomedicine
(904)
Gastrointestinal Stromal Tumors - Drug Therapy
(892)
Oncology
(572)
Imatinib Mesylate
(529)
Male
(499)
Antineoplastic Agents - Therapeutic Use
(489)
Female
(450)
Middle Aged
(438)
Gastrointestinal Stromal Tumors - Pathology
(418)
Benzamides
(394)
Tumors
(393)
Pyrimidines - Therapeutic Use
(362)
Piperazines - Therapeutic Use
(356)
Aged
(347)
Imatinib
(334)
Gastrointestinal Stromal Tumors - Genetics
(308)
Adult
(306)
Mutation
(292)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.095)
MEDLINE
(1.028)
Journals@Ovid
(361)
IngentaConnect Journals
(360)
IngentaConnect Journals
(330)
NUS Single-Journal Subscriptions
(254)
SpringerLink (Online service)
(127)
Wiley-Blackwell Journals
(108)
Nature Journals Online
(75)
Wiley Online Library
(47)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(44)
Nexis Uni (LexisNexis)
(44)
Taylor & Francis Journals
(43)
ScienceDirect
(37)
Taylor & Francis E-Journals
(33)
BMJ_英国医学会期刊
(31)
Taylor & Francis
(30)
Oxford Journals
(25)
Oxford Journals 2020 Medicine
(21)
SpringerLink Series
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

Gastrointestinal Stromal Tumors

The management of metastatic GIST: current standard and investigational therapeutics

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial

Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Aktive Filter

Suchergebnisse filtern